

Title (en)
OPIOID ANTAGONIST CONTAINING COMPOSITION FOR ENHANCING THE POTENCY OR REDUCING ADVERSE SIDE EFFECTS OF OPIOID AGONISTS

Title (de)
ANWENDUNG VON OPIOID ANTAGONISTEN ZUR FÖRDERUNG DER AKTION ODER ZUR VERRINGERUNG VON UNERWÜNSCHTEN NEBENWIRKUNGEN VON OPIOID AGONISTEN

Title (fr)
NOUVELLES COMPOSITIONS ET METHODES DESTINEES A AMELIORER LA PUISSANCE OU REDUIRE LES EFFETS SECONDAIRES INDESIRABLES D'AGONISTES OPIOIDES

Publication
EP 1280529 A2 20030205 (EN)

Application
EP 01933110 A 20010504

Priority

- US 0114644 W 20010504
- US 20226800 P 20000505
- US 20222700 P 20000505
- US 56607100 A 20000505
- US 0012493 W 20000505
- US 24448200 P 20001030
- US 24511000 P 20001101
- US 24623500 P 20001102
- US 75633101 A 20010108

Abstract (en)
[origin: WO0185150A2] The invention generally relates to novel compositions and methods with an opioid agonist and an opioid antagonist to differentially dose a human subject so as to either enhance analgesic potency without attenuating an adverse side effect of the agonist, or alternatively maintain the analgesic potency of the agonist while attenuating an adverse side effect of the agonist. The invention additionally relates to novel opioid compositions and methods for the gender-based dosing of men and women.
[origin: WO0185150A2] The invention generally relates to novel compositions and methods with an opioid agonist and an opioid antagonist to differentially dose a human subject so as to either enhance analgesic potency without attenuating an adverse side effect of the agonist, or alternatively maintain the analgesic potency of the agonist while attenuating an adverse side effect of the agonist. The invention additionally relates to novel opioid compositions and methods for the gender-based dosing of men and women.

IPC 1-7
A61K 31/485

IPC 8 full level
A61K 9/20 (2006.01); **A61K 9/48** (2006.01); **A61K 9/50** (2006.01); **A61K 31/00** (2006.01); **A61K 31/135** (2006.01); **A61K 31/167** (2006.01); **A61K 31/445** (2006.01); **A61K 31/485** (2006.01); **A61K 45/06** (2006.01); **A61P 25/04** (2006.01); **A61P 29/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 9/2018 (2013.01); **A61K 9/2054** (2013.01); **A61K 9/4858** (2013.01); **A61K 9/4866** (2013.01); **A61K 9/5042** (2013.01); **A61K 9/5084** (2013.01); **A61K 31/00** (2013.01); **A61K 31/135** (2013.01); **A61K 31/445** (2013.01); **A61K 31/485** (2013.01); **A61K 45/06** (2013.01); **A61P 25/04** (2017.12); **A61P 29/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)
See references of WO 0185150A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0185150 A2 20011115; **WO 0185150 A3 20020808**; AU 2001259458 B2 20060914; AU 2001259560 B2 20070215; AU 5956001 A 20011120; CA 2408098 A1 20011115; EP 1280529 A2 20030205; JP 2004501094 A 20040115

DOCDB simple family (application)
US 0114644 W 20010504; AU 2001259458 A 20010504; AU 2001259560 A 20010504; AU 5956001 A 20010504; CA 2408098 A 20010504; EP 01933110 A 20010504; JP 2001581804 A 20010504